ruby_Current_Folio_S8

As filed with the Securities and Exchange Commission on May 15, 2019

Registration No. 333‑

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S‑8

REGISTRATION STATEMENT

Under

The Securities Act of 1933

RUBIUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware

 

46‑ 2688109

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification Number)

399 Binney Street, Suite 300

Cambridge, Massachusetts

(617) 679‑9600

(Address of Principal Executive Offices)

Rubius Therapeutics, Inc. 2018 Stock Option and Incentive Plan

Rubius Therapeutics, Inc. 2018 Employee Stock Purchase Plan

(Full Title of the Plans)


Pablo J. Cagnoni,  Chief Executive Officer

399 Binney Street, Suite 300

Cambridge, Massachusetts

(617) 679‑9600

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Stuart M. Cable, Esq.

Arthur McGivern, Esq.

Goodwin Procter LLP

100 Northern Avenue

Boston, Massachusetts 02210

(617) 570‑1000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

 

 

 

Large accelerated filer ☐

 

Accelerated filer ☐

Non-accelerated filer ☒

 

Smaller reporting company ☐

 

 

Emerging growth company ☒ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

CALCULATION OF REGISTRATION FEE

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Title of Securities
to be Registered

 

Amount
to be
Registered(1)

 

Proposed
Maximum
Offering Price
per Share (2)

 

Proposed
Maximum
Aggregate
Offering Price

 

Amount of
Registration
Fee (2)

 

Common Stock, $0.001 par value per share 

 

2,377,045 shares 

(3)

$

15.41 

 

$

36,630,263.45 

 

$

4,439.59 

 

Common Stock, $0.001 par value per share 

 

792,348 shares 

(4) 

$

15.41 

 

$

12,210,082.68 

 

$

1,479.86 

 

Total

 

3,169,393 shares 

 

 

 

 

$

48,840,346.13 

 

$

5,919.45 

 

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, this Registration Statement shall also cover any additional shares of common stock which become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. Pursuant to Rule 416(c) under the Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plans described herein.

(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on $15.41, the average (rounded to the nearest cent) of the high and low sale prices of the Registrant’s common stock as reported on the Nasdaq Global Select Market on May 8, 2019.

(3) Represents an automatic increase to the number of shares available for issuance under the Registrant’s 2018 Stock Option and Incentive Plan (the “Plan”), effective as of January 1, 2019. Shares available for issuance under the Plan were previously registered on Form S‑8 filed with the Securities and Exchange Commission on July 18, 2018 (Registration No. 333‑226226).

(4) Represents an automatic increase to the number of shares available for issuance under the Registrant’s  2018 Employee Stock Purchase Plan (the “ESPP”), effective as of January 1, 2019. Shares available for issuance under the ESPP were previously registered on Form S‑8 filed with the Securities and Exchange Commission on July 18, 2018 (Registration No. 333‑226226).

 

 

 

 


 

EXPLANATORY NOTE

This Registration Statement on Form S‑8 registers additional shares of the Registrant’s common stock, par value $0.001 (the “Common Stock”) under the Registrant’s 2018 Stock Option and Incentive Plan (the “Plan”) and the Registrant’s 2018 Employee Stock Purchase Plan (the “ESPP”). The number of shares of Common Stock reserved and available for issuance under the Plan is subject to an automatic annual increase on each January 1, beginning in 2019, by an amount equal to four percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or such lesser number of shares of Common Stock as determined by the Administrator of our Plan (as defined in the Plan). Accordingly, on January 1, 2019, the number of shares of Common Stock reserved and available for issuance under the Plan increased by 2,377,045  shares. The number of shares of Common Stock reserved and available for issuance under the ESPP is subject to an automatic annual increase on each January 1, beginning in 2019, by the lesser of (i) 951,488 shares of Common Stock, (ii) 1% of the outstanding shares of Common Stock on the immediately preceding December 31 or (iii) such lesser number of shares as determined by the Administrator of our ESPP (as defined in the ESPP). Accordingly, on January 1, 2019, the number of shares of Common Stock reserved and available for issuance under the ESPP increased by 792,348 shares. This Registration Statement on Form S‑8 registers these additional 3,169,393 shares of Common Stock. The additional shares are of the same class as other securities relating to the plans for which the Registrant’s registration statement filed on Form S‑8 (Registration No. 333‑226226) on July 18, 2018 is effective. The information contained in the Registrant’s registration statement on Form S‑8 (Registration No. 333‑226226) is hereby incorporated by reference pursuant to General Instruction E.

Part II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Registration Statement, which Exhibit Index is incorporated herein by reference.


 

EXHIBIT INDEX

 

 

Exhibit
No. 

    

Description

 

 

 

4.1

 

Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8‑K filed on July 23, 2018 (File No. 001‑38586)).

 

 

 

4.2

 

Amended and Restated Bylaws of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8‑K filed on July 23, 2018 (File No. 001‑38586)).

 

 

 

4.3

 

Specimen Common Stock Certificate (Incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S‑1, as amended (File No. 333 225840) filed on July 2, 2018)).

 

 

 

4.4

 

Second Amended and Restated Investors’ Rights Agreement by and among the Registrant and certain of its stockholders, dated February 23, 2018 (Incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S‑1 (File No. 333‑225840) filed on June 22, 2018). 

 

 

 

5.1*

 

Opinion of Goodwin Procter LLP. 

 

 

 

23.1*

 

Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm. 

 

 

 

23.2*

 

Consent of Goodwin Procter LLP (included in Exhibit 5.1). 

 

 

 

24.1*

 

Power of Attorney (included on signature page). 

 

 

 

99.1

 

2018 Stock Option and Incentive Plan, and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S‑1, as amended (File No. 333‑225840)). 

 

 

 

99.2

 

2018 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S‑1, as amended (File No. 333‑225840)). 


*Filed herewith.


 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on the 15th day of May, 2019.

 

 

 

 

RUBIUS THERAPEUTICS, INC. 

 

 

 

 

By:

/s/ Pablo J. Cagnoni

 

 

Pablo J. Cagnoni

 

 

Chief Executive Officer 

POWER OF ATTORNEY AND SIGNATURES

KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Pablo Cagnoni and Andrew Oh as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S‑8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

 

 

 

 

 

Name

    

Title

    

Date

/s/ Pablo J. Cagnoni

 

Chief Executive Officer, Director (Principal Executive Officer)

 

May 15, 2019

Pablo J. Cagnoni

 

 

 

 

 

 

 

 

 

 

 

Chairman, Director

 

May 15, 2019

David R. Epstein

 

 

 

 

 

 

 

 

 

/s/ Andrew M. Oh

 

Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

 

May 15, 2019

Andrew M. Oh

 

 

 

 

 

 

 

 

 

/s/ Noubar B. Afeyan

 

Director

 

May 15, 2019

Noubar B. Afeyan, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Francis Cuss

 

Director

 

May 15, 2019

Francis Cuss, M.B., B.Chir., FRCP

 

 

 

 

 

 

 

 

 

/s/ Robert S. Langer

 

Director

 

May 15, 2019

Robert S. Langer, Sc.D.

 

 

 

 

 

 

 

 

 

/s/ Natalie Holles

 

Director

 

May 15, 2019

Natalie Holles

 

 

 

 

 

 

 

 

 

/s/ Roger Pomerantz

 

Director

 

May 15, 2019

Roger Pomerantz, M.D.

 

 

 

 

 

 

 

 

 

/s/ Michael Rosenblatt

 

Director

 

May 15, 2019

Michael Rosenblatt, M.D.

 

 

 

 

 

 

 

 

 

/s/ Catherine A. Sohn

 

Director

 

May 15, 2019

Catherine A. Sohn, Pharm.D.

 

 

 

 

 

 

 

 

 

 

 

Director

 

May 15, 2019

Jonathan R. Symonds, CBE

 

 

 

 

 


ruby_Ex5_1

Exhibit 5.1

 

Picture 1

Goodwin Procter LLP

100 Northern Avenue

Boston, MA 02210

goodwinlaw.com

+1 617 570 1000

 

May 15, 2019

 

Rubius Therapeutics, Inc.

399 Binney Street, Suite 300

Cambridge, Massachusetts

 

Re:Securities Being Registered under Registration Statement on Form S-8

 

Ladies and Gentlemen:

 

We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-8 (the “Registration Statement”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), on or about the date hereof relating to an aggregate of  3,169,393 shares (the “Shares”) of Common Stock, $0.001 par value per share (“Common Stock”), of  Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), that may be issued pursuant to the Company’s 2018 Stock Option and Incentive Plan and 2018 Employee Stock Purchase Plan (collectively, the “Plans”).

 

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below.  We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

 

The opinion set forth below is limited to the Delaware General Corporation Law.

 

For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.

 

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.

 

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement.  In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

 

 

Very truly yours,

 

 

 

/S/ GOODWIN PROCTER LLP

 

 

 

GOODWIN PROCTER  LLP

 

 


ruby_Ex23_1

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Rubius Therapeutics, Inc. of our report dated March 28, 2019 relating to the financial statements, which appears in Rubius Therapeutics, Inc.'s Annual Report on Form 10‑K for the year ended December 31, 2018.

 

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

May 15, 2019